MONMOUTH JUNCTION, N.J., Aug. 18, 2011 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, has appointed Mr. Dominick DiPaolo to the position of Vice President of Quality, and Mr. Adam Drapczuk III as Controller and Director of Finance. They bring extensive backgrounds in their respective areas of expertise to the company as the newest members of Tris leadership team.
“Tris’ emphasis on innovation has paid dividends via a rich pipeline and several FDA approved products. Now with multiple branded and generic regulatory filings under FDA review, it was imperative to strengthen our investment in Quality, creating a new position of Vice President of Quality. Further, as these products come to market, financial management will grow ever more complex necessitating the need for dedicated financial leadership. We were fortunate to have identified and recruited two top tier seasoned managers in Dominick and Adam,” said Ketan Mehta, President and CEO of Tris Pharma.
Dominick started his career in quality and compliance at big pharma. After initial stints at Ortho, Schering-Plough, Roche and Novartis, he was a Senior Manager of Global Corporate Quality at Pfizer from 2002 to 2005. Since 2005 to 2011 he led Quality operations at three different generic companies mostly in remedial situations starting with Barr (formerly Pliva, Inc.), then Wockhardt Pharmaceuticals (Morton Grove) and most recently at G&W Laboratories. He is a graduate of Rutgers University. At Tris, Dominick will be in charge of all aspects of Quality and will be expanding the current quality team at Tris.
Adam is a Certified Public Accountant and a graduate of Sigmund Weis School of Business at Susquehanna University. He started his career at KPMG LLP in 1998 and worked with small and large client companies in all aspects of financial operations. In 2002 he moved to the pharmaceutical industry with last seven years in increasing capacities including Controller and Director of Finance at WestWard Pharmaceutical Corp. At Tris, Adam will be responsible for all accounting and financial activities and reporting. He will be reporting to the CEO.
About Tris Pharma
Tris Pharma is a specialty pharmaceutical company focused on the research and development of drug delivery technologies based products. Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris’ Nobuse platform provides abuse-deterrence for opioids and other abuse-prone drugs. Tris’ R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, please visit www.trispharma.com.
SOURCE Tris Pharma
